Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are chromaffin-cell tumors that arise from the adrenal medulla and extra-adrenal paraganglia, respectively. The dysfunction of genes involved in the cellular response to hypoxia, such as VHL, EGL nine homolog 1, and the succinate dehydrogenase (SDH) genes, leads to a direct abrogation of hypoxia inducible factor (HIF) degradation, resulting in a pseudo-hypoxic state implicated in PCC/PGL development. Recently, somatic post-zygotic mutations in EPAS1 (HIF2A) have been found in patients with multiple PGLs and congenital erythrocytosis. We assessed 41 PCCs/PGLs for mutations in EPAS1 and herein describe the clinical, molecular and genetic characteristics of the 7 patients found to carry somatic EPAS1 mutations; 4 presented with multiple PGLs (3 of them also had congenital erythrocytosis), whereas 3 were single sporadic PCC/PGL cases. Gene expression analysis of EPAS1-mutated tumors revealed similar mRNA EPAS1 levels to those found in SDH-gene- and VHL-mutated cases and a significant up-regulation of two hypoxia-induced genes (PCSK6 and GNA14). Interestingly, single nucleotide polymorphism array analysis revealed an exclusive gain of chromosome 2p in three EPAS1-mutated tumors. Furthermore, multiplex-PCR screening for small rearrangements detected a specific EPAS1 gain in another EPAS1-mutated tumor and in three non-EPAS1-mutated cases. The finding that EPAS1 is involved in the sporadic presentation of the disease not only increases the percentage of PCCs/PGLs with known driver mutations, but also highlights the relevance of studying other hypoxia-related genes in apparently sporadic tumors. Finally, the detection of a specific copy number alteration affecting chromosome 2p in EPAS1-mutated tumors may guide the genetic diagnosis of patients with this disease.

[1]  Davis J. McCarthy,et al.  Erythrocytosis associated with a novel missense mutation in the BPGM gene , 2010, Haematologica.

[2]  E. Letouzé,et al.  Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. , 2012, Human molecular genetics.

[3]  C. Larsson,et al.  Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. , 2012, Human molecular genetics.

[4]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[5]  G. Reifenberger,et al.  Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion‐associated candidate genes , 2012, Neuropathology and applied neurobiology.

[6]  M. McMullin,et al.  Two new mutations in the HIF2A gene associated with erythrocytosis , 2012, American journal of hematology.

[7]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[8]  M. Percy,et al.  The HIF pathway and erythrocytosis. , 2011, Annual review of pathology.

[9]  Paolo Vineis,et al.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 , 2011, Nature Genetics.

[10]  Agnieszka Maliszewska,et al.  Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. , 2010, Molecular endocrinology.

[11]  P. Bénit,et al.  SDHA is a tumor suppressor gene causing paraganglioma. , 2010, Human molecular genetics.

[12]  E. Huizinga,et al.  Erythrocytosis associated with a novel missense mutation in the HIF2A gene , 2010, Haematologica.

[13]  Patricia L. M. Dahia,et al.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.

[14]  Steven P. Gygi,et al.  SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma , 2009, Science.

[15]  E. van Marck,et al.  An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. , 2009, The Lancet. Oncology.

[16]  Ramón Díaz-Uriarte,et al.  Pomelo II: finding differentially expressed genes , 2009, Nucleic Acids Res..

[17]  A. Green,et al.  Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. , 2008, Blood.

[18]  M. McMullin,et al.  A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. , 2008, The New England journal of medicine.

[19]  G. Gurtner,et al.  Hypoxia up‐regulates the angiogenic cytokine secretoneurin via an HIF‐1α‐ and basic FGF‐dependent pathway in muscle cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Jin Xu,et al.  Extracellular ATP-dependent upregulation of the transcription cofactor LMO4 promotes neuron survival from hypoxia. , 2007, Experimental cell research.

[21]  A. Harris,et al.  Transcriptional Profiling of Human Cord Blood CD133+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia , 2007, Stem cells.

[22]  Sonja W. Scholz,et al.  Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. , 2007, Human molecular genetics.

[23]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[24]  B. Martínez-Delgado,et al.  Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot? , 2006, Genes, chromosomes & cancer.

[25]  A. Klein-Szanto,et al.  PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. , 2005, Cancer research.

[26]  P. Maxwell.  A common pathway for genetic events leading to pheochromocytoma. , 2005, Cancer cell.

[27]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[28]  Y. Wong,et al.  Signal Transducer and Activator of Transcription 3 Activation by the δ-Opioid Receptor via Gα14 Involves Multiple Intermediates , 2004 .

[29]  Y. Wong,et al.  Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. , 2004, Molecular pharmacology.

[30]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[31]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[32]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[33]  I. Lubensky,et al.  Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. , 2000, Cancer research.

[34]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[35]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[36]  P. Corvol,et al.  Cloning and expression pattern of EPAS1 in the chicken embryo , 1999, FEBS letters.

[37]  S. McKnight,et al.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. , 1997, Genes & development.

[38]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[39]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[40]  Thomas W. Glover,et al.  A de novo Alu insertion results in neurofibromatosis type 1 , 1991, Nature.

[41]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .